Back to Journals » OncoTargets and Therapy » Volume 11

Association between IL-17A G197A polymorphism and gastric cancer risk: an updated meta-analysis based on 6,624 cases and 7,631 controls

Authors Hu L, Kong F, Pan Y

Received 7 September 2017

Accepted for publication 1 December 2017

Published 5 February 2018 Volume 2018:11 Pages 703—710

DOI https://doi.org/10.2147/OTT.S151129

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Faris Farassati


Lixia Hu,1 Fanliang Kong,1 Yueyin Pan2

1Department of Oncology, The Second People’s Hospital of Hefei, Hefei, Anhui, China; 2Department of Oncology, Anhui Province Hospital, Hefei, Anhui, China

Purpose: Previous studies investigating the association between interleukin-17A (IL-17A) G197A polymorphism and gastric cancer risk have provided inconsistent results. We, therefore, conducted this meta-analysis to clarify the association between IL-17A G197A polymorphism and gastric cancer risk.
Methods: We searched PubMed, Excerpta Medica Database, and CNKI databases to identify relevant studies up to June 10, 2017. A total of 16 case-control studies including 6,624 cases and 7,631 controls were identified.
Results: Overall, significant associations between IL-17A G197A polymorphism and gastric cancer risk were observed (A vs G: OR =1.24, 95% CI =1.14–1.36; AA vs GG: OR =1.63, 95% CI =1.35–1.96; GA vs GG: OR =1.12, 95% CI =1.01–1.25; AA+GA vs GG: OR =1.23, 95% CI =1.11–1.35; AA vs GA+GG: OR =1.54, 95% CI =1.27–1.87). Similar associations were also observed in Asian population (A vs G: OR =1.25, 95% CI =1.15–1.37; AA vs GG: OR =1.62, 95% CI =1.33–1.97; GA vs GG: OR =1.16, 95% CI =1.07–1.25; AA+GA vs GG: OR =1.24, 95% CI =1.15–1.33; AA vs GA+GG: OR =1.51, 95% CI =1.23–1.85), in Caucasian population (AA vs GA+GG: OR =2.19, 95% CI =1.40–3.44), and in the hospital-based controls’ subgroup (A vs G: OR =1.30, 95% CI =1.17–1.45; AA vs GG: OR =1.81, 95% CI =1.46–2.25; AA+GA vs GG: OR =1.27, 95% CI =1.12–1.43; AA vs GA+GG: OR =1.71, 95% CI =1.34–2.18).
Conclusions: The current meta-analysis suggests that IL-17A G197A polymorphism might enhance gastric cancer risk.

Keywords: gastric cancer, polymorphism, meta-analysis, interleukin-17A, rs2275913
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]